Loading
A phase 1/2 trial of Ipilimumab, Nivolumab, Gemcitabine in mesothelioma and non-small-cell lung cancer, run by Orion Corporation, Orion Pharma, now recruiting.
A 2-part Phase 1/2 Open-label Trial on ODM-212 is a phase 1/2 interventional study registered as NCT07563738 by Orion Corporation, Orion Pharma, with 229 participants planned, started 2026-03-27 and due to reach its primary completion in 2029-09. Interventions recorded: ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel, sotorasib. Conditions listed: Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ipilimumab, Paclitaxel / nab-paclitaxel, Nivolumab, Small-cell lung cancer.
Shares Mesothelioma, Ipilimumab, Nivolumab, Small-cell lung cancer.
Shares Ipilimumab, Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Mesothelioma, Ipilimumab, Nivolumab.
Shares Sotorasib, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Mesothelioma, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Mesothelioma, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Mesothelioma, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/